Finance

Lists
Why is SOBI up २.२४%?
Dive Deeper
SOBI:STO
Swedish Orphan Biovitrum AB (publ)
SEK ४९३.४०
+२.२४%
(+१०.८०) 1D
नोभेम्बर ५, ११:०१:४८ GMT+१  ·   SEK
All symbols
SymbolPriceChange% Change
Generating top insights for SOBI...
Open
SEK ४८६.००
High
SEK ४९४.००
Low
SEK ४८४.२०
Mkt. cap
१.७६ खरब
Avg. vol.
३.३८ लाख
Volume
४३.७९ हजार
P/E ratio
२६.२१
52-wk high
SEK ४९४.००
52-wk low
SEK ३१४.४०
EPS
SEK १८.८३
Shares outstanding
३५.७६ करोड
No. of employees
२ हजार
Open
SEK ४८६.००
High
SEK ४९४.००
Low
SEK ४८४.२०
Mkt. cap
१.७६ खरब
Avg. vol.
३.३८ लाख
Volume
४३.७९ हजार
P/E ratio
२६.२१
52-wk high
SEK ४९४.००
52-wk low
SEK ३१४.४०
EPS
SEK १८.८३
Shares outstanding
३५.७६ करोड
No. of employees
२ हजार
News stories
From web sources and news partners
TradingView
TradingView
·
१ दिन पहिले
Swedish Orphan Biovitrum Executive Sells, Buys Shares
Profile
Sobi - Swedish Orphan Biovitrum AB is an international biopharmaceutical company focused on rare diseases. The company develops, commercializes, and delivers therapies in the fields of haematology, immunology and specialty care. Headquartered in Stockholm, Sweden, with major hubs in Basel, Switzerland, and Waltham, USA. Sobi has a global presence in approximately 30 countries and provides medicines to patients in many more around world. The company develops treatments for patients living with complex and chronic rare conditions and maintains a pipeline of development and lifecycle management programs focused on advancing innovative therapies for diseases with significant unmet medical needs. Wikipedia
About Swedish Orphan Biovitrum AB (publ)
CEOGuido Oelkers
Employees२.२१ हजार
Founded१९३९
Headquarters-
Sector-
Industry-
Websitesobi.com
Previous reportsAll values in SEK
Loading Previous Earnings...
Revenue
Net income
All values in SEK
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
२०२६ सेप्टेम्बर
Revenue
७.८२ अरब
७.१८ अरब
७.८४ अरब
९.१२ अरब
Cost of goods sold
१.५१ अरब
१.७० अरब
१.८३ अरब
१.९३ अरब
Cost of revenue
१.५१ अरब
१.७० अरब
१.८३ अरब
१.९३ अरब
Research and development expenses
८७.९० करोड
९४.८० करोड
१.१३ अरब
१.०७ अरब
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
२.९३ अरब
२.६२ अरब
२.८९ अरब
२.८३ अरब
Operating expense
३.७५ अरब
३.५७ अरब
४.०३ अरब
३.८७ अरब
Total operating expenses
५.२६ अरब
५.२७ अरब
५.८६ अरब
५.८० अरब
Operating income
२.५६ अरब
१.९१ अरब
१.९८ अरब
३.३२ अरब
Other non operating income
-२.५० करोड
१०.०० लाख
१०.०० लाख
१०.०० लाख
EBT including unusual items
२.१७ अरब
१.६८ अरब
१.४१ अरब
३.०४ अरब
EBT excluding unusual items
२.३२ अरब
१.७२ अरब
१.७७ अरब
३.१४ अरब
Income tax expense
३१.०० करोड
३६.३० करोड
३१.५० करोड
६८.९० करोड
Effective tax rate
१४.२७%
२१.५९%
२२.२९%
२२.६८%
Other operating expenses
-५.७० करोड
१०.०० लाख
८०.०० लाख
-२.६० करोड
Net income
१.८६ अरब
१.३२ अरब
१.१० अरब
२.३५ अरब
Net profit margin
२३.८१%
१८.३५%
१३.९९%
२५.७६%
Earnings per share
५.६५
४.०७
३.९६
६.८९
Interest and investment income
२.२० करोड
-
-
-
Interest expense
-१५.६० करोड
-१७.३० करोड
-२०.४० करोड
-२०.४० करोड
Net interest expenses
-१३.४० करोड
-१७.३० करोड
-२०.४० करोड
-२०.४० करोड
Depreciation and amortization charges
-
-
-
-
EBITDA
३.१३ अरब
२.६९ अरब
२.७८ अरब
४.१३ अरब
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google एपहरू